BACKGROUND/AIMS: Previous studies have demonstrated that during transition from
chronic liver disease to hepatocellular carcinoma (HCC), autoantibodies can appear which …

Objective It remains controversial whether tumour mutational burden (TMB) or neoantigens
are prognostic markers in hepatocellular carcinoma (HCC). This study aimed to define the …

Despite advances in our cellular and molecular knowledge, hepatocellular carcinoma
(HCC) remains one of the major public health problems throughout the world. It is now …

Simple Summary The incidence of liver cancer is increasing worldwide. When detected
early, the most common form of primary liver cancer (hepatocellular carcinoma, or HCC) can …

Purpose: The prognosis of patients with advanced biliary tract cancer (BTC) is extremely
poor and there are only a few standard treatments. We conducted a phase I trial to …

Due to its widespread occurrence and high mortality rate, hepatocellular carcinoma (HCC) is
an abhorrent kind of cancer. Immunotherapy is a hot spot in the field of cancer treatment …

Recent genome‐wide cDNA microarray analysis of gene expression profiles in
comprehensive tumor types coupled with isolation of cancer tissues by laser‐microbeam …

BACKGROUND To identify antigens specifically recognized by the immune surveillance
system in patients with hepatocellular carcinoma (HCC), the authors examined two …

Background The tumor immunological microenvironment (TIME) has a prominent impact on
prognosis and immunotherapy. However, the heterogeneous TIME and the mechanisms by …

Many human tumor-associated antigens (TAAs) have recently been identified and
molecularly characterized. When bound to major histocompatibility complex molecules, TAA …